[go: up one dir, main page]

CO2021009693A2 - Proteínas de unión a antígeno del receptor gamma anti-il2 - Google Patents

Proteínas de unión a antígeno del receptor gamma anti-il2

Info

Publication number
CO2021009693A2
CO2021009693A2 CONC2021/0009693A CO2021009693A CO2021009693A2 CO 2021009693 A2 CO2021009693 A2 CO 2021009693A2 CO 2021009693 A CO2021009693 A CO 2021009693A CO 2021009693 A2 CO2021009693 A2 CO 2021009693A2
Authority
CO
Colombia
Prior art keywords
antibodies
binding proteins
gamma receptor
receptor antigen
fragments
Prior art date
Application number
CONC2021/0009693A
Other languages
English (en)
Inventor
Andrew J Murphy
Jamie M Orengo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2021009693A2 publication Critical patent/CO2021009693A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

RESUMEN La presente invención proporciona anticuerpos y fragmentos de unión a antígeno (por ejemplo, anticuerpos humanos) que se unen específicamente al receptor gamma de IL2 humana (IL2R). También se proporcionan métodos para tratar o prevenir enfermedades mediadas por IL2R (por ejemplo, enfermedad de injerto contra huésped) usando los anticuerpos y fragmentos junto con métodos para fabricar los anticuerpos y fragmentos.
CONC2021/0009693A 2019-02-01 2021-07-23 Proteínas de unión a antígeno del receptor gamma anti-il2 CO2021009693A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799851P 2019-02-01 2019-02-01
PCT/US2020/015841 WO2020160242A1 (en) 2019-02-01 2020-01-30 Anti-il2 receptor gamma antigen-binding proteins

Publications (1)

Publication Number Publication Date
CO2021009693A2 true CO2021009693A2 (es) 2021-08-09

Family

ID=69740681

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0009693A CO2021009693A2 (es) 2019-02-01 2021-07-23 Proteínas de unión a antígeno del receptor gamma anti-il2

Country Status (16)

Country Link
US (2) US11629195B2 (es)
EP (1) EP3917962A1 (es)
JP (2) JP7544724B2 (es)
KR (1) KR20210123350A (es)
CN (3) CN120157765A (es)
AU (1) AU2020214812A1 (es)
BR (1) BR112021014074A2 (es)
CA (1) CA3126117A1 (es)
CL (1) CL2021002008A1 (es)
CO (1) CO2021009693A2 (es)
EA (1) EA202192090A1 (es)
IL (1) IL284579A (es)
MX (1) MX2021008958A (es)
PH (1) PH12021500031A1 (es)
SG (1) SG11202107272SA (es)
WO (1) WO2020160242A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126117A1 (en) * 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
EP4139341A1 (en) * 2020-04-21 2023-03-01 Regeneron Pharmaceuticals, Inc. Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
CA3236138A1 (en) * 2021-11-02 2023-05-11 Shiyong GONG Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
CN114990206B (zh) * 2022-06-02 2023-04-07 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Common γ-chain受体作为药物靶点在制备治疗狼疮性肾炎药物中的应用
WO2024015418A1 (en) 2022-07-13 2024-01-18 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
KR20250075694A (ko) 2022-09-28 2025-05-28 리제너론 파마슈티칼스 인코포레이티드 세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체
CN118459574B (zh) * 2022-10-21 2025-06-17 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
WO2024138175A1 (en) * 2022-12-22 2024-06-27 Forte Subsidiary, Inc. Methods of treating acute and chronic graft versus host diseases
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
WO1997017360A2 (en) 1995-11-09 1997-05-15 Dana-Farber Cancer Institute Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain
AU2937597A (en) 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
WO2001077288A2 (en) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2006239851B2 (en) 2005-04-26 2011-06-16 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
JP6060073B2 (ja) 2010-04-08 2017-01-11 ジェイエヌ バイオサイエンシーズ エルエルシー Ｃｄ１２２に対する抗体
US9469685B2 (en) * 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
PL3366705T3 (pl) 2012-09-12 2023-09-18 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
HUE046065T2 (hu) 2014-07-21 2020-01-28 Delinia Inc Szabályozó T-sejteket szelektíven aktiváló molekulák autoimmun betegségek kezelésére
CN107922496B (zh) * 2015-08-06 2022-11-01 新加坡科技研究局 IL2Rβ/通用γ链抗体
TW201722989A (zh) * 2015-10-23 2017-07-01 輝瑞大藥廠 抗il-2抗體及其組合物及用途
WO2018156649A1 (en) 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
CA3126117A1 (en) * 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins

Also Published As

Publication number Publication date
CL2021002008A1 (es) 2022-02-04
SG11202107272SA (en) 2021-07-29
CA3126117A1 (en) 2020-08-06
JP2022519068A (ja) 2022-03-18
IL284579A (en) 2021-08-31
WO2020160242A1 (en) 2020-08-06
US20200247894A1 (en) 2020-08-06
KR20210123350A (ko) 2021-10-13
JP7544724B2 (ja) 2024-09-03
CN113474370B (zh) 2025-04-01
US20230279131A1 (en) 2023-09-07
US11629195B2 (en) 2023-04-18
EA202192090A1 (ru) 2021-10-20
CN120157765A (zh) 2025-06-17
CN120157766A (zh) 2025-06-17
AU2020214812A1 (en) 2021-09-23
EP3917962A1 (en) 2021-12-08
PH12021500031A1 (en) 2022-05-02
MX2021008958A (es) 2021-11-04
CN113474370A (zh) 2021-10-01
JP2024161548A (ja) 2024-11-19
BR112021014074A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
CU20170169A7 (es) Anticuerpos de factor xi
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
MX2018004531A (es) Proteinas de union a antigeno que activan el receptor de leptina.
CO2019007686A2 (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo
BR112016024214B8 (pt) Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
CL2021000146A1 (es) Anticuerpos humanizados contra psma
ECSP21046332A (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
CL2019000426A1 (es) Anticuerpo o un fragmento de unión a antígeno del mismo, capaz de unirse a un receptor humano de interleucina-6.
EA202190504A1 (ru) Способы лечения псориаза
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
AR119964A2 (es) Anticuerpos anti-cd123 y conjugados y derivados de estos
AR118787A1 (es) Moléculas de unión a pd-l1 y uso de las mismas para el tratamiento de enfermedades
BR112017019075A2 (pt) anticorpo anti-esclerostina, fragmento de ligação ao antígeno e uso médico desses